abiraterone acetate + enzalutamide

Abiraterone acetate + enzalutamide refers to the alternative hormonal therapy intervention arm in the Phase 3 clinical trial NCT04139772, sponsored by the National Cancer Institute, Naples. This trial evaluates the efficacy of switching to an alternative hormonal agent (either abiraterone acetate or enzalutamide) compared to docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on a prior hormonal therapy. Abiraterone acetate is a small molecule inhibitor of the CYP17A1 enzyme, which is critical for androgen biosynthesis in the testes, adrenal glands, and prostate tumor tissue; it is typically administered with prednisone to manage mineralocorticoid excess. Enzalutamide is a small molecule androgen receptor (AR) antagonist that competitively inhibits androgen binding, AR nuclear translocation, and DNA binding. The trial aims to determine if sequential hormonal therapy is a viable alternative to chemotherapy in the second-line setting for asymptomatic or oligosymptomatic mCRPC patients.

Brand names

ZytigaXtandi

Other names

Abiraterone Acetate or EnzalutamideHormone Therapy switch